With the accumulation of craftsmanship, Meiya Pharmaceuticals CPHI China 2025 came to a successful conclusion!

From June 24 to 26, the 23rd CPHI China Exhibition was held in Shanghai New International Expo Center.

As one of the domestic nucleotide companies with the most complete categories, Meiya Pharmaceuticals brought a full range of nucleotide products to CPHI to show global buyers the research and development and production strength of "China's Intelligent Manufacturing" nucleosides and their derivatives!

From basic nucleosides to mRNA raw materials, from enzyme preparations to immune enhancers, Meiya Pharmaceuticals has reached more than 60 specifications after years of hard work. Its business covers API, pharmaceutical intermediates, animal health, functional food additives, diagnostic reagents, cosmetic raw materials and other fields, showing the continued vitality of nucleosides and their derivatives.

At this conference, Meiya Pharmaceutical received 200 domestic and foreign customers. The scene was very lively, and everyone discussed the current situation and future of the pharmaceutical industry together!

Although the exhibition has ended, Meiya's pace of innovation will never stop. Here, we would like to express our special thanks to every customer and expert who came to the booth to communicate. Your insights are the driving force for our progress.

The sales, R&D, production, and logistics teams working behind the scenes have made the word "professional" come true.

For our partners who have trusted us for a long time, we will return this trust with better products and more efficient services in the future.

We will see you again on June 16-18, 2026!